COLORADO SPRINGS, Colo., The Spectranetics Corporation (NASDAQ:SPNC) today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance of its peripheral atherectomy product, the ...
The Spectranetics Corporation announced receipt of FDA 510(k) clearance of their peripheral atherectomy products, Turbo-Tandem and Turbo Elite, for the treatment of in-stent restenosis, or ISR. "FDA ...
According to a recent press release, Colorado Springs-based Spectranetics announced that it has received FDA 510(k) clearance for its Turbo-Power™ Laser Atherectomy Catheter, a peripheral atherectomy ...
Spectranetics to Initiate Landmark Randomized Study of Laser Treatment for Peripheral Artery Disease
The study will compare the safety and efficacy of excimer laser atherectomy utilizing the Spectranetics’ Turbo-Tandem and Turbo Elite products in conjunction with balloon angioplasty, with that of ...
First of all, from the PAD growth overall in the market I think the third-party data sources that are out there, are showing the PAD, I believes it’s rolling in the mid to lower teens and I think if ...
Spectranetics To Initiate Landmark Randomized Study Of Laser Treatment For Peripheral Artery Disease
Spectranetics Corporation today announced that it plans to initiate the EXCITE ISR (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis) clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results